We find ourselves today at a critical juncture in the market introduction of groundbreaking therapies. After years of promise, 2017 finally marked the first approval of a gene therapy in the US, Novartis’ Kymriah, with the approval of Kite’s Yescarta and Spark Therapeutics’ Luxturna soon thereafter. To date, there are more than 500 clinical trials for gene therapies in the US alone, 34 of which are in pivotal stages, and there is significant activity in other key geographies. The arrival of these therapies portends disruption in the industry—being able to treat heretofore incurable conditions, but at prices that concentrate significant treatment costs for these patients over a short period of time and in the hands of only one industry stakeholder, the pharmaceutical manufacturer.
To read more, click here.
Articles
Cell and Gene Therapy: Building Winning Strategies in a Disrupted Industry
March 14, 2018
Key contacts
Upcoming events
Informa: EU Pharmaceutical Law Forum 2026
CRA is a proud sponsor the event featuring authority insights from the EU Commission, Competition Authorities, EMA and leading pharmaceutical...
ThoughtLeaders4: 3rd Annual UK Competition Law
CRA is a proud sponsor of the summit. Simon Chisholm is a speaker during the session titled “Understanding Lessons and Takeaways from Market Investigations”...